AU2010214301B2 - Anti-MST1R antibodies and uses thereof - Google Patents
Anti-MST1R antibodies and uses thereof Download PDFInfo
- Publication number
- AU2010214301B2 AU2010214301B2 AU2010214301A AU2010214301A AU2010214301B2 AU 2010214301 B2 AU2010214301 B2 AU 2010214301B2 AU 2010214301 A AU2010214301 A AU 2010214301A AU 2010214301 A AU2010214301 A AU 2010214301A AU 2010214301 B2 AU2010214301 B2 AU 2010214301B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- acid sequence
- amino acid
- antibody
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15141109P | 2009-02-10 | 2009-02-10 | |
| US61/151,411 | 2009-02-10 | ||
| PCT/JP2010/052479 WO2010093055A1 (en) | 2009-02-10 | 2010-02-10 | Anti-mst1r antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010214301A1 AU2010214301A1 (en) | 2011-09-01 |
| AU2010214301B2 true AU2010214301B2 (en) | 2016-11-10 |
Family
ID=42227811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010214301A Ceased AU2010214301B2 (en) | 2009-02-10 | 2010-02-10 | Anti-MST1R antibodies and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9403909B2 (https=) |
| EP (1) | EP2396084B1 (https=) |
| JP (1) | JP5714511B2 (https=) |
| KR (1) | KR101745025B1 (https=) |
| CN (1) | CN102438702B (https=) |
| AU (1) | AU2010214301B2 (https=) |
| BR (1) | BRPI1007979A2 (https=) |
| CA (1) | CA2752136C (https=) |
| CO (1) | CO6420322A2 (https=) |
| ES (1) | ES2583281T3 (https=) |
| IL (1) | IL214527A0 (https=) |
| MX (1) | MX2011008456A (https=) |
| NZ (1) | NZ594452A (https=) |
| RU (1) | RU2534890C2 (https=) |
| SG (2) | SG2014009195A (https=) |
| TW (1) | TWI480050B (https=) |
| WO (1) | WO2010093055A1 (https=) |
| ZA (1) | ZA201105725B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356749B (es) * | 2012-04-27 | 2018-06-12 | Daiichi Sankyo Co Ltd | Anticuerpo anti-homologo 4 de roundabout (robo4). |
| TWI909341B (zh) | 2015-09-24 | 2025-12-21 | 日商第一三共股份有限公司 | 抗garp抗體及其製造方法及用途 |
| EP3504244A4 (en) | 2016-08-26 | 2020-08-19 | Agency for Science, Technology and Research | MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES |
| MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
| WO2021066751A1 (en) * | 2019-10-02 | 2021-04-08 | Aslan Pharmaceuticals Pte. Ltd. | Antigen specific binding domains and antibody molecules |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005120557A2 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| US20060073256A1 (en) * | 2004-06-15 | 2006-04-06 | Frederic Destaillats | Self-foaming liquid creamers and processes |
| JP2008512352A (ja) * | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| UY31478A1 (es) * | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
| MX2010008025A (es) * | 2008-01-22 | 2010-08-04 | Biogen Idec Inc | Anticuerpos ron y usos de los mismos. |
-
2010
- 2010-02-09 TW TW099103887A patent/TWI480050B/zh not_active IP Right Cessation
- 2010-02-10 EP EP10710107.3A patent/EP2396084B1/en not_active Not-in-force
- 2010-02-10 WO PCT/JP2010/052479 patent/WO2010093055A1/en not_active Ceased
- 2010-02-10 CN CN201080016662.8A patent/CN102438702B/zh not_active Expired - Fee Related
- 2010-02-10 RU RU2011137405/10A patent/RU2534890C2/ru not_active IP Right Cessation
- 2010-02-10 KR KR1020117018586A patent/KR101745025B1/ko not_active Expired - Fee Related
- 2010-02-10 SG SG2014009195A patent/SG2014009195A/en unknown
- 2010-02-10 NZ NZ594452A patent/NZ594452A/xx not_active IP Right Cessation
- 2010-02-10 MX MX2011008456A patent/MX2011008456A/es active IP Right Grant
- 2010-02-10 CA CA2752136A patent/CA2752136C/en not_active Expired - Fee Related
- 2010-02-10 BR BRPI1007979A patent/BRPI1007979A2/pt not_active IP Right Cessation
- 2010-02-10 ES ES10710107.3T patent/ES2583281T3/es active Active
- 2010-02-10 AU AU2010214301A patent/AU2010214301B2/en not_active Ceased
- 2010-02-10 JP JP2011548901A patent/JP5714511B2/ja not_active Expired - Fee Related
- 2010-02-10 SG SG2011055175A patent/SG173196A1/en unknown
-
2011
- 2011-08-03 ZA ZA2011/05725A patent/ZA201105725B/en unknown
- 2011-08-08 IL IL214527A patent/IL214527A0/en not_active IP Right Cessation
- 2011-08-10 US US13/206,736 patent/US9403909B2/en not_active Expired - Fee Related
- 2011-08-23 CO CO11106887A patent/CO6420322A2/es active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005120557A2 (en) * | 2004-05-13 | 2005-12-22 | Imclone Systems Incorporated | Inhibition of macrophage-stimulating protein receptor (ron) |
Non-Patent Citations (1)
| Title |
|---|
| O'TOOLE J.M. et al., "Therapeutic Implications of a Human Neutralizing Antibody to the Macrophge-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member", Cancer Research, 15 September 2006, Vol. 66, No. 18 pages 9162-9170 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2396084B1 (en) | 2016-05-11 |
| AU2010214301A1 (en) | 2011-09-01 |
| US9403909B2 (en) | 2016-08-02 |
| KR20110117677A (ko) | 2011-10-27 |
| WO2010093055A1 (en) | 2010-08-19 |
| TW201036635A (en) | 2010-10-16 |
| SG173196A1 (en) | 2011-08-29 |
| IL214527A0 (en) | 2011-09-27 |
| KR101745025B1 (ko) | 2017-06-20 |
| US20120034215A1 (en) | 2012-02-09 |
| HK1164193A1 (zh) | 2012-09-21 |
| CO6420322A2 (es) | 2012-04-16 |
| RU2534890C2 (ru) | 2014-12-10 |
| RU2011137405A (ru) | 2013-03-20 |
| TWI480050B (zh) | 2015-04-11 |
| JP5714511B2 (ja) | 2015-05-07 |
| EP2396084A1 (en) | 2011-12-21 |
| ZA201105725B (en) | 2012-04-25 |
| MX2011008456A (es) | 2011-09-26 |
| SG2014009195A (en) | 2014-04-28 |
| BRPI1007979A2 (pt) | 2017-10-03 |
| ES2583281T3 (es) | 2016-09-20 |
| CN102438702A (zh) | 2012-05-02 |
| JP2012517223A (ja) | 2012-08-02 |
| CA2752136A1 (en) | 2010-08-19 |
| CN102438702B (zh) | 2016-03-02 |
| CA2752136C (en) | 2016-03-15 |
| NZ594452A (en) | 2013-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102343742B1 (ko) | 항-pd-l1 항체 | |
| DK2215121T3 (en) | ANTI-mesothelin ANTIBODIES AND USES THEREOF | |
| JP5362359B2 (ja) | ヒトCD38に特異的な完全ヒトHuCALGOLD由来の治療抗体の生成とプロファイリング | |
| KR20140006713A (ko) | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 | |
| CN107428838B (zh) | 结合tfpi的新型抗体以及包含所述抗体的组合物 | |
| AU2010214301B2 (en) | Anti-MST1R antibodies and uses thereof | |
| CN107427563B (zh) | 人源化α-烯醇酶特异性抗体及用于癌症治疗的方法 | |
| US20110110944A1 (en) | Anti-alk1 antibodies and uses thereof | |
| CN1976950B (zh) | 抗cd38人抗体及其用途 | |
| CN114729013B (zh) | 抗cd22抗体及其用途 | |
| KR20140138533A (ko) | 항 igf-1r 단일클론 항체 및 이를 포함하는 암치료용 조성물 | |
| HK1164193B (en) | Anti-mst1r antibodies and uses thereof | |
| HK1261643B (en) | Anti-pd-l1 antibodies | |
| HK1132752A1 (en) | Novel antiproliferation antibodies | |
| HK1132752B (en) | Novel antiproliferation antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |